Advanced in Supranuclear Ocular Palsy

Dr. Adam L. Boxer

Neurology
University Of California San Francisco
2330 Post St, 
San Francisco, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Advanced in Supranuclear Ocular Palsy
University Of California San Francisco
2330 Post St, 
San Francisco, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Adam Boxer is a Neurologist in San Francisco, California. Dr. Boxer is rated as an Advanced provider by MediFind in the treatment of Supranuclear Ocular Palsy. His top areas of expertise are Progressive Supranuclear Palsy, Progressive Supranuclear Palsy Atypical, Supranuclear Ophthalmoplegia, and Corticobasal Degeneration.

His clinical research consists of co-authoring 339 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in CA
Hospital Affiliations
Ucsf Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

UNIVERSITY OF CALIFORNIA SAN FRANCISCO
2330 Post St, San Francisco, CA 94115

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Enrollment Status: Recruiting
Publish Date: February 28, 2024
Observational Longitudinal Study of Magnetic Resonance Imaging, Specimen Biomarkers, and Clinical Progression in Progressive Supranuclear Palsy and Corticobasal Degeneration
Observational Longitudinal Study of Magnetic Resonance Imaging, Specimen Biomarkers, and Clinical Progression in Progressive Supranuclear Palsy and Corticobasal Degeneration
Enrollment Status: Completed
Publish Date: May 08, 2025
Intervention Type: Other
A Phase 1b, 12-Month, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Salsalate in Patients With Mild to Moderate Alzheimer's Disease
A Phase 1b, 12-Month, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Salsalate in Patients With Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: April 16, 2025
Intervention Type: Drug
Study Drug: Salsalate
Study Phase: Phase 1
The Four-Repeat Tauopathy Neuroimaging Initiative
The Four-Repeat Tauopathy Neuroimaging Initiative
Enrollment Status: Completed
Publish Date: April 13, 2025
Intervention Type: Other
Remote Blood Biomarker Monitoring in Frontotemporal Lobar Degeneration: Neurofilament Surveillance Project (NSP)
Remote Blood Biomarker Monitoring in Frontotemporal Lobar Degeneration: Neurofilament Surveillance Project (NSP)
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2025
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Trial Ready Cohort for the Prevention of Alzheimer's Dementia (TRC-PAD)
Enrollment Status: Completed
Publish Date: June 27, 2024
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Enrollment Status: Completed
Publish Date: December 28, 2023
Intervention Type: Drug
Study Drug: Solanezumab
Study Phase: Phase 3
A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia
A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia
Enrollment Status: Active_not_recruiting
Publish Date: December 15, 2023
Intervention Type: Drug
Study Drug: Syntocinon
Study Phase: Phase 2
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
Rare Diseases Clinical Research Network Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Projects 1 & 2
Rare Diseases Clinical Research Network Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Projects 1 & 2
Enrollment Status: Completed
Publish Date: May 21, 2021
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 2
A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy
A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy
Enrollment Status: Completed
Publish Date: April 01, 2021
Intervention Type: Drug
Study Phase: Phase 1
A 6 Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear Palsy
A 6 Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear Palsy
Enrollment Status: Completed
Publish Date: August 11, 2020
Intervention Type: Biological
Study Phase: Phase 1
A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BIIB092 in Patients With Progressive Supranuclear Palsy Who Participated in Study CN002003
A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BIIB092 in Patients With Progressive Supranuclear Palsy Who Participated in Study CN002003
Enrollment Status: Terminated
Publish Date: May 18, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel Cohort Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Intravenously Infused BIIB092 in Patients With Four Different Primary Tauopathy Syndromes
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel Cohort Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Intravenously Infused BIIB092 in Patients With Four Different Primary Tauopathy Syndromes
Enrollment Status: Terminated
Publish Date: December 19, 2019
Intervention Type: Other, Drug
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy
A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy
Enrollment Status: Completed
Publish Date: September 04, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 16 Less Clinical Trials

331 Total Publications

Neurodegenerative plasma biomarkers for prediction of hippocampal atrophy in older adults with suspected Alzheimer's disease in Kinshasa, Democratic Republic of Congo.
Neurodegenerative plasma biomarkers for prediction of hippocampal atrophy in older adults with suspected Alzheimer's disease in Kinshasa, Democratic Republic of Congo.
Journal: Journal of Alzheimer's disease : JAD
Published: July 30, 2025
Similar Doctors
Distinguished in Supranuclear Ocular Palsy
Dr. Ian O. Bledsoe
Neurology
Distinguished in Supranuclear Ocular Palsy
Dr. Ian O. Bledsoe
Neurology

University Of California San Francisco

400 Parnassus Ave, Mcb300, 
San Francisco, CA 
 (1.7 miles away)
415-476-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ian Bledsoe is a Neurologist in San Francisco, California. Dr. Bledsoe is rated as a Distinguished provider by MediFind in the treatment of Supranuclear Ocular Palsy. His top areas of expertise are Drug Induced Dyskinesia, Movement Disorders, Parkinson's Disease, Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency, and Deep Brain Stimulation.

Advanced in Supranuclear Ocular Palsy
Dr. Julio C. Rojas-Martinez
Neurology
Advanced in Supranuclear Ocular Palsy
Dr. Julio C. Rojas-Martinez
Neurology

Ucsf Medical Group Business Services

400 Parnassus Ave, 
San Francisco, CA 
 (1.7 miles away)
415-476-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Julio Rojas-Martinez is a Neurologist in San Francisco, California. Dr. Rojas-Martinez is rated as an Advanced provider by MediFind in the treatment of Supranuclear Ocular Palsy. His top areas of expertise are Progressive Supranuclear Palsy Atypical, Supranuclear Ocular Palsy, Progressive Supranuclear Palsy, and Supranuclear Ophthalmoplegia.

Advanced in Supranuclear Ocular Palsy
Dr. Chadwick W. Christine
Neurology
Advanced in Supranuclear Ocular Palsy
Dr. Chadwick W. Christine
Neurology

University Of California San Francisco

2330 Post St, 
San Francisco, CA 
 (0.1 miles away)
415-476-4029
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Chadwick Christine is a Neurologist in San Francisco, California. Dr. Christine is rated as a Distinguished provider by MediFind in the treatment of Supranuclear Ocular Palsy. His top areas of expertise are Parkinson's Disease, Movement Disorders, Vitamin B12 Deficiency Anemia, and Essential Tremor.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Boxer's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 8 Advanced Conditions
View All 18 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile